<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281580</url>
  </required_header>
  <id_info>
    <org_study_id>1235.1</org_study_id>
    <secondary_id>2008-000874-19</secondary_id>
    <nct_id>NCT00281580</nct_id>
  </id_info>
  <brief_title>Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Placebo-controlled, 4x4 Factorial Design Trial to Evaluate Telmisartan 20, 40 and 80 mg Tablets in Combination With Amlodipine 2.5, 5 and 10 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To demonstrate that Micardis and Norvasc when used together are more effective at lowering
      blood pre ssure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Diastolic Blood Pressure (DBP) (Observed Telmisartan Effect)</measure>
    <time_frame>Baseline to end-of-study (up to 8 weeks) visit (Last Observation Carried Forward (LOCF))</time_frame>
    <description>Observed results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)</measure>
    <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects)</measure>
    <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Observed results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)</measure>
    <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Treatment Effects)</measure>
    <time_frame>End-of-study visit (LOCF)</time_frame>
    <description>Observed results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects)</measure>
    <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)</measure>
    <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Seated Trough Cuff Mean DBP (Observed Telmisartan Effect)</measure>
    <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Observed results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)</measure>
    <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects)</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Observed results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Seated Trough Cuff Mean DBP (Observed Treatment Effects)</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Observed results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects)</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 8 Weeks in Standing Trough Cuff Mean DBP</measure>
    <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 8 Weeks in Standing Trough Cuff Mean SBP</measure>
    <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP Control</measure>
    <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>DBP control is defined as DBP &lt; 90 mmHg - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP Response</measure>
    <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>DBP response is defined as DBP &lt; 90 mmHg or a reduction of DBP of &gt;= 10 mmHg - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Response</measure>
    <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>SBP Response is defined as SBP &lt; 140 mmHg or a reduction of SBP of &gt;= 10 mmHg - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Normality</measure>
    <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>No: Mean seated SBP &gt;=140 and/or mean seated DBP &gt;=90 mmHg at trough High normal: mean seated SBP &gt;=130 and &lt;140 mmHg and mean seated DBP &gt;=85 and &lt;90 mmHg at trough Normal: mean seated SBP &gt;=120 and &lt;130 mmHg and mean seated DBP &gt;=80 and &lt;85 mmHg at trough Optimal: mean seated SBP &lt; 120 mmHg and mean seated DBP &lt;80 mmHg at trough
- key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP</measure>
    <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Observed results - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ABPM Hourly Mean (Relative to Dosing) SBP</measure>
    <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Observed results - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ABPM 24-hour Mean DBP</measure>
    <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Observed results - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ABPM 24-hour Mean SBP</measure>
    <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Observed results - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orthostatic Change in Trough Cuff Mean DBP</measure>
    <time_frame>Week 8</time_frame>
    <description>Calculated as seated minus standing for all patients - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orthostatic Change in Trough Cuff Mean SBP</measure>
    <time_frame>Week 8</time_frame>
    <description>Calculated as seated minus standing for all patients - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Seated Trough Pulse Rate</measure>
    <time_frame>End-of-study visit (LOCF)</time_frame>
    <description>Observed results for all patients - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Seated Trough Cuff Mean SBP</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Standing Trough Cuff Mean DBP</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Standing Trough Cuff Mean SBP</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP Control</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>DBP control is defined as DBP &lt; 90 mmHg - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DBP Response</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>DBP response is defined as DBP &lt; 90 mmHg or a reduction of DBP of &gt;= 10 mmHg - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Response</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>SBP Response is defined as SBP &lt; 140 mmHg or a reduction of SBP of &gt;= 10 mmHg - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Normality</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>No: Mean seated SBP &gt;=140 and/or mean seated DBP &gt;=90 mmHg at trough High normal: mean seated SBP &gt;=130 and &lt;140 mmHg and mean seated DBP &gt;=85 and &lt;90 mmHg at trough Normal: mean seated SBP &gt;=120 and &lt;130 mmHg and mean seated DBP &gt;=80 and &lt;85 mmHg at trough Optimal: mean seated SBP &lt; 120 mmHg and mean seated DBP &lt;80 mmHg at trough
- key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Observed results for mod-sev patients - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ABPM 24-hour Mean DBP</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Observed results for mod-sev patients - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ABPM 24-hour Mean SBP</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Observed results for mod-sev patients - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orthostatic Change in Trough Cuff Mean DBP</measure>
    <time_frame>Week 8</time_frame>
    <description>Calculated as seated minus standing for mod-sev patients - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orthostatic Change in Trough Cuff Mean SBP</measure>
    <time_frame>Week 8</time_frame>
    <description>Calculated as seated minus standing for mod-sev patients - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Seated Trough Pulse Rate</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Observed results for mod-sev patients - key combination therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Laboratory Parameters and Electrocardiogram (ECG)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Clinical relevant abnormalities for laboratory parameters and Electrocardiogram (ECG). New abnormal findings or worsening of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline at 2,4,6,and 8 Weeks in Seated Trough Cuff DBP</measure>
    <time_frame>Baseline to nominal week over the trial</time_frame>
    <description>Observed results for key combination therapies</description>
  </other_outcome>
  <other_outcome>
    <measure>BP Control</measure>
    <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
    <description>Percentage of responders (SBP&lt;140 mmHg and DBP&lt;90 mmHg) for all patients - key combination therapies</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Seated Trough Cuff DBP</measure>
    <time_frame>Nominal week over the trial</time_frame>
    <description>Observed results for mod-sev patients - key combination therapies</description>
  </other_outcome>
  <other_outcome>
    <measure>BP Control</measure>
    <time_frame>Up to 8 weeks (LOCF)</time_frame>
    <description>Responders SBP&lt;10 mmHg and DBP&lt;90 mmHg) for mod-sev patients - key combination therapies</description>
  </other_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">1461</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 20 mg once daily for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 40 mg once daily for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 80 mg once daily for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 2.5 mg once daily for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 5 mg once daily for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine 5 mg for two weeks and forced titrated to amlodipine 10 mg for six weeks once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 20 / Amlodipine 2.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 20/ Amlodipine 2.5 mg once daily for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 20 / Amlodipine 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 20 / Amlodipine 5 mg once daily for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 20 / Amlodipine 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 20 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 40 / Amlodipine 2.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 40 / Amlodipine 2.5 for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 40 / Amlodipine 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 40 / Amlodipine 5 for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 40 / Amlodipine 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 80 / Amlodipine 2.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 80 / Amlodipine 2.5 for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 80 / Amlodipine 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 80 / Amlodipine 5 mg for eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 80 / Amlodipine 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5 mg</intervention_name>
    <description>Amlodipine 5 mg once daily for two weeks</description>
    <arm_group_label>Telmisartan 80 / Amlodipine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to Telmisartan and Amlodipine once daily for eight weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 20 mg</intervention_name>
    <description>Telmisartan 20 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 40 mg</intervention_name>
    <description>Telmisartan 40 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 40 / Amlodipine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10 mg</intervention_name>
    <description>Amlodipine 10 mg once daily for six weeks</description>
    <arm_group_label>Telmisartan 20 / Amlodipine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 20 mg</intervention_name>
    <description>Telmisartan 20 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 20 / Amlodipine 2.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80 mg</intervention_name>
    <description>Telmisartan 80 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 80 / Amlodipine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10 mg</intervention_name>
    <description>Amlodipine 10 mg once daily for six weeks</description>
    <arm_group_label>Telmisartan 80 / Amlodipine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 20 mg</intervention_name>
    <description>Telmisartan 20 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 20 / Amlodipine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5 mg</intervention_name>
    <description>Amlodipine 5 mg once daily for two weeks</description>
    <arm_group_label>Telmisartan 20 / Amlodipine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5 mg</intervention_name>
    <description>amlodipine 5g once daily for eight weeks</description>
    <arm_group_label>Amlodipine 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 20 mg</intervention_name>
    <description>Telmisartan 20 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 20 / Amlodipine 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5 mg</intervention_name>
    <description>Amlodipine 5 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 40 / Amlodipine 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5 mg</intervention_name>
    <description>amlodipine 5mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 20 / Amlodipine 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 2.5 mg</intervention_name>
    <description>Amlodipine 2.5 mg once daily for eight weeks</description>
    <arm_group_label>Amlodipine 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 2.5 mg</intervention_name>
    <description>Amlodipine 2.5 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 80 / Amlodipine 2.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10 mg</intervention_name>
    <description>Amlodipine 10 mg once daily for six weeks</description>
    <arm_group_label>Telmisartan 40 / Amlodipine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 2.5 mg</intervention_name>
    <description>Amlodipine 2.5 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 40 / Amlodipine 2.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80 mg</intervention_name>
    <description>Telmisartan 80 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80 mg</intervention_name>
    <description>Telmisartan 80 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 80 / Amlodipine 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5 mg</intervention_name>
    <description>Amlodipine 5 mg once daily for two weeks</description>
    <arm_group_label>Telmisartan 40 / Amlodipine 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 2.5 mg</intervention_name>
    <description>Amlodipine 2.5 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 20 / Amlodipine 2.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 40 mg</intervention_name>
    <description>Telmisartan 40 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 40 / Amlodipine 2.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 40 mg</intervention_name>
    <description>Telmisartan 40 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 40 / Amlodipine 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5 mg</intervention_name>
    <description>amlodipine 5g once daily for two weeks</description>
    <arm_group_label>Amlodipine 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5 mg</intervention_name>
    <description>Amlodipine 5 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 80 / Amlodipine 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 40 mg</intervention_name>
    <description>Telmisartan 40 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80 mg</intervention_name>
    <description>Telmisartan 80 mg once daily for eight weeks</description>
    <arm_group_label>Telmisartan 80 / Amlodipine 2.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10 mg</intervention_name>
    <description>Amlodipine 10 mg once daily for six weeks</description>
    <arm_group_label>Amlodipine 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Main Inclusion Criteria: Male and female patients &gt;=18 years of age with Stage I or II
        hypertension defined as: a mean seated cuff diastolic blood pressure &gt;=95 and &lt;=119 mmHg
        Main

        Exclusion criteria:

        Exclusion Criteria:

          1. Patient is pregnant; breast-feeding; unwilling to use birth control during the study;
             has secondary hypertension; severe renal dysfunction; hepatic insufficiency; stroke
             within the last six months; myocardial infarction, cardiac surgery, percutaneous
             transluminal coronary angioplasty, unstable angina or coronary artery bypass graft
             within the past three months; unstable or uncontrolled diabetes for the past three
             months defined as a glucosylates hemoglobin (HbA1c) greater than ten percent ; history
             of angioedema or hypersensitivity related to either study drug.

          2. Systolic Blood Pressure (SBP) is greater than or equal to 180 millimeters of mercury
             (mmHg), Diastolic Blood Pressure (DBP) is greater than or equal to 110 mmHg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.1.457 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.368 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.389 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.411 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.429 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.420 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.391 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cudahy</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.444 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.445 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.357 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.465 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.441 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.414 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.383 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.395 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.453 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.394 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.354 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.451 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.372 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.396 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.390 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.430 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.351 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.398 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mirimar</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.352 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.369 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.397 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.449 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.355 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rockledge</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.380 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.438 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.373 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.375 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.415 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.412 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.435 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arkansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.379 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.421 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newtown</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.356 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.423 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.387 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.424 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.385 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.452 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.365 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.431 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.454 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.426 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.434 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stratford</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.366 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.377 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Northport</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.427 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.381 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.400 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.422 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenior</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.376 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.392 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.384 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.458 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.374 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.446 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.413 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.359 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.361 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.436 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.448 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.386 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.439 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.440 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.428 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Penndel</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.370 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.433 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beaufort</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.462 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.417 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.459 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.363 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Tazewell</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.382 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Selmer</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.442 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.399 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.460 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.443 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.416 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.432 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.456 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.418 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.455 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.358 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.464 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.437 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.447 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.371 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>BsAs</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carlos Paz</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.115 Universidade Federal do Par</name>
      <address>
        <city>Belm</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.102 Liga de Hipertenso Arterial</name>
      <address>
        <city>Goiania</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.101 Clnica Mdica</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.103 Unidade de Hipertenso - ICHC -</name>
      <address>
        <city>So Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.109 Centro de Pesquisas do Hospital do Rim e Hipertenso</name>
      <address>
        <city>So Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.203</name>
      <address>
        <city>Col. Magdalena de las Salinas</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.210 Consultorio Privado</name>
      <address>
        <city>Durango, Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.202</name>
      <address>
        <city>Guadalajara, Jalisco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guadalajara, Jalisco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.204</name>
      <address>
        <city>Lomas de Guevara, Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.208 &quot;Ignacio Chvez&quot;</name>
      <address>
        <city>mexico DF</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.211 Obesidad Y Prevencion de Enfermedades</name>
      <address>
        <city>Mexico, D.F.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.212 en Factores de riesgo cardiovascular</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.205 Fraccionamiento Industrias</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.207</name>
      <address>
        <city>Zapopan, Jalisco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.314 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Benoni</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boksburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.309 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.310 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.311 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.312 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.313 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.307 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenasia</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenasia</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.1.308 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Mexico</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2006</study_first_submitted>
  <study_first_submitted_qc>January 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <results_first_submitted>November 18, 2009</results_first_submitted>
  <results_first_submitted_qc>March 26, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2010</results_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Pl)</title>
          <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
        </group>
        <group group_id="P2">
          <title>Telmisartan 20 mg (T20)</title>
          <description>Telmisartan 20mg tablet, QD in morning</description>
        </group>
        <group group_id="P3">
          <title>Telmisartan 40 mg (T40)</title>
          <description>Telmisartan 40mg tablet, QD in morning</description>
        </group>
        <group group_id="P4">
          <title>Telmisartan 80 mg (T80)</title>
          <description>Telmisartan 80mg tablet, QD in morning</description>
        </group>
        <group group_id="P5">
          <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
          <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
        </group>
        <group group_id="P6">
          <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
          <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
        </group>
        <group group_id="P7">
          <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
          <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
        </group>
        <group group_id="P8">
          <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
          <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
        </group>
        <group group_id="P9">
          <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
          <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
        </group>
        <group group_id="P10">
          <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
          <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
        </group>
        <group group_id="P11">
          <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
          <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
        </group>
        <group group_id="P12">
          <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
          <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
        </group>
        <group group_id="P13">
          <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
          <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
        </group>
        <group group_id="P14">
          <title>Amlodipine 2.5 mg (A2.5)</title>
          <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
        </group>
        <group group_id="P15">
          <title>Amlodipine 5 mg (A5)</title>
          <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
        </group>
        <group group_id="P16">
          <title>Amlodipine 10 mg (A10)</title>
          <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="130"/>
                <participants group_id="P4" count="135"/>
                <participants group_id="P5" count="44"/>
                <participants group_id="P6" count="46"/>
                <participants group_id="P7" count="44"/>
                <participants group_id="P8" count="47"/>
                <participants group_id="P9" count="143"/>
                <participants group_id="P10" count="129"/>
                <participants group_id="P11" count="48"/>
                <participants group_id="P12" count="146"/>
                <participants group_id="P13" count="142"/>
                <participants group_id="P14" count="50"/>
                <participants group_id="P15" count="140"/>
                <participants group_id="P16" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="125"/>
                <participants group_id="P4" count="118"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="43"/>
                <participants group_id="P7" count="39"/>
                <participants group_id="P8" count="46"/>
                <participants group_id="P9" count="135"/>
                <participants group_id="P10" count="117"/>
                <participants group_id="P11" count="44"/>
                <participants group_id="P12" count="136"/>
                <participants group_id="P13" count="129"/>
                <participants group_id="P14" count="43"/>
                <participants group_id="P15" count="133"/>
                <participants group_id="P16" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="10"/>
                <participants group_id="P13" count="13"/>
                <participants group_id="P14" count="7"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomised in error; pregnancy; moving</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set including all 1461 patients who were randomised to receive double-blind treatment and took at least one dose.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Pl)</title>
          <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
        </group>
        <group group_id="B2">
          <title>Telmisartan 20 mg (T20)</title>
          <description>Telmisartan 20mg tablet, QD in morning</description>
        </group>
        <group group_id="B3">
          <title>Telmisartan 40 mg (T40)</title>
          <description>Telmisartan 40mg tablet, QD in morning</description>
        </group>
        <group group_id="B4">
          <title>Telmisartan 80 mg (T80)</title>
          <description>Telmisartan 80mg tablet, QD in morning</description>
        </group>
        <group group_id="B5">
          <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
          <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
        </group>
        <group group_id="B6">
          <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
          <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
        </group>
        <group group_id="B7">
          <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
          <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
        </group>
        <group group_id="B8">
          <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
          <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
        </group>
        <group group_id="B9">
          <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
          <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
        </group>
        <group group_id="B10">
          <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
          <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
        </group>
        <group group_id="B11">
          <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
          <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
        </group>
        <group group_id="B12">
          <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
          <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
        </group>
        <group group_id="B13">
          <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
          <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
        </group>
        <group group_id="B14">
          <title>Amlodipine 2.5 mg (A2.5)</title>
          <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
        </group>
        <group group_id="B15">
          <title>Amlodipine 5 mg (A5)</title>
          <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
        </group>
        <group group_id="B16">
          <title>Amlodipine 10 mg (A10)</title>
          <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
        </group>
        <group group_id="B17">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="130"/>
            <count group_id="B4" value="135"/>
            <count group_id="B5" value="44"/>
            <count group_id="B6" value="46"/>
            <count group_id="B7" value="44"/>
            <count group_id="B8" value="47"/>
            <count group_id="B9" value="143"/>
            <count group_id="B10" value="129"/>
            <count group_id="B11" value="48"/>
            <count group_id="B12" value="146"/>
            <count group_id="B13" value="142"/>
            <count group_id="B14" value="50"/>
            <count group_id="B15" value="140"/>
            <count group_id="B16" value="129"/>
            <count group_id="B17" value="1461"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="12.3"/>
                    <measurement group_id="B2" value="53.6" spread="10.4"/>
                    <measurement group_id="B3" value="52" spread="11"/>
                    <measurement group_id="B4" value="53.1" spread="11.3"/>
                    <measurement group_id="B5" value="54" spread="10.8"/>
                    <measurement group_id="B6" value="54.4" spread="10.2"/>
                    <measurement group_id="B7" value="51" spread="11.2"/>
                    <measurement group_id="B8" value="50.7" spread="10.2"/>
                    <measurement group_id="B9" value="52.3" spread="11.9"/>
                    <measurement group_id="B10" value="53.3" spread="11.3"/>
                    <measurement group_id="B11" value="54.8" spread="9.7"/>
                    <measurement group_id="B12" value="52.7" spread="11.9"/>
                    <measurement group_id="B13" value="53.9" spread="11.6"/>
                    <measurement group_id="B14" value="55.3" spread="10.4"/>
                    <measurement group_id="B15" value="53.1" spread="10.6"/>
                    <measurement group_id="B16" value="53.4" spread="10.7"/>
                    <measurement group_id="B17" value="53.1" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="21"/>
                    <measurement group_id="B9" value="72"/>
                    <measurement group_id="B10" value="67"/>
                    <measurement group_id="B11" value="26"/>
                    <measurement group_id="B12" value="72"/>
                    <measurement group_id="B13" value="78"/>
                    <measurement group_id="B14" value="23"/>
                    <measurement group_id="B15" value="68"/>
                    <measurement group_id="B16" value="64"/>
                    <measurement group_id="B17" value="724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="26"/>
                    <measurement group_id="B9" value="71"/>
                    <measurement group_id="B10" value="62"/>
                    <measurement group_id="B11" value="22"/>
                    <measurement group_id="B12" value="74"/>
                    <measurement group_id="B13" value="64"/>
                    <measurement group_id="B14" value="27"/>
                    <measurement group_id="B15" value="72"/>
                    <measurement group_id="B16" value="65"/>
                    <measurement group_id="B17" value="737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Diastolic Blood Pressure (DBP) (Observed Telmisartan Effect)</title>
        <description>Observed results</description>
        <time_frame>Baseline to end-of-study (up to 8 weeks) visit (Last Observation Carried Forward (LOCF))</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 0 mg (T0)</title>
            <description>Overall: including Pl, A2.5, A5, and A10 treated groups</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Overall: including all treatment groups involving T20</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Overall: including all treatment groups involving T40</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Overall: including all treatment groups involving T80</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Diastolic Blood Pressure (DBP) (Observed Telmisartan Effect)</title>
          <description>Observed results</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="457"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13" spread="8.8"/>
                    <measurement group_id="O2" value="-16.4" spread="7.8"/>
                    <measurement group_id="O3" value="-16.2" spread="8.9"/>
                    <measurement group_id="O4" value="-16.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
        <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 0 mg (T0)</title>
            <description>Overall: including Pl, A2.5, A5, and A10 treated groups</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Overall: including all treatment groups involving T20</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Overall: including all treatment groups involving T40</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Overall: including all treatment groups involving T80</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="440"/>
                <count group_id="O4" value="457"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="0.5"/>
                    <measurement group_id="O2" value="-16.8" spread="0.6"/>
                    <measurement group_id="O3" value="-16.6" spread="0.4"/>
                    <measurement group_id="O4" value="-17.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects)</title>
        <description>Observed results</description>
        <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Amlodipine 10 mg (A10)</title>
            <description>monotherapy (A5 titrated to A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects)</title>
          <description>Observed results</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="466"/>
                <count group_id="O4" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.3" spread="9.7"/>
                    <measurement group_id="O2" value="-14.9" spread="8.8"/>
                    <measurement group_id="O3" value="-15.6" spread="8.1"/>
                    <measurement group_id="O4" value="-18.6" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
        <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Amlodipine 10 mg (A10)</title>
            <description>monotherapy (A5 titrated to A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="466"/>
                <count group_id="O4" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="0.5"/>
                    <measurement group_id="O2" value="-15.3" spread="0.6"/>
                    <measurement group_id="O3" value="-16.2" spread="0.4"/>
                    <measurement group_id="O4" value="-19.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Treatment Effects)</title>
        <description>Observed results</description>
        <time_frame>End-of-study visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Telmisartan 20mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Telmisartan 40mg tablet, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Telmisartan 80mg tablet, QD in morning</description>
          </group>
          <group group_id="O5">
            <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
            <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O6">
            <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
            <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O7">
            <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
            <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O8">
            <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
            <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O9">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O10">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O11">
            <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
            <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O12">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O13">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O14">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O15">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O16">
            <title>Amlodipine 10 mg (A10)</title>
            <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Treatment Effects)</title>
          <description>Observed results</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="129"/>
                <count group_id="O4" value="132"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="123"/>
                <count group_id="O11" value="46"/>
                <count group_id="O12" value="143"/>
                <count group_id="O13" value="136"/>
                <count group_id="O14" value="48"/>
                <count group_id="O15" value="137"/>
                <count group_id="O16" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="9.4"/>
                    <measurement group_id="O2" value="-13.2" spread="9"/>
                    <measurement group_id="O3" value="-13.1" spread="10.1"/>
                    <measurement group_id="O4" value="-13.6" spread="8.7"/>
                    <measurement group_id="O5" value="-18" spread="7.8"/>
                    <measurement group_id="O6" value="-15.7" spread="6.5"/>
                    <measurement group_id="O7" value="-18.7" spread="7"/>
                    <measurement group_id="O8" value="-16.2" spread="8.2"/>
                    <measurement group_id="O9" value="-16" spread="7.6"/>
                    <measurement group_id="O10" value="-19.6" spread="7.9"/>
                    <measurement group_id="O11" value="-15.3" spread="7.5"/>
                    <measurement group_id="O12" value="-17.8" spread="8.5"/>
                    <measurement group_id="O13" value="-19.6" spread="7.9"/>
                    <measurement group_id="O14" value="-10.4" spread="9.9"/>
                    <measurement group_id="O15" value="-13" spread="7.9"/>
                    <measurement group_id="O16" value="-16.5" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects)</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
        <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Telmisartan 20mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Telmisartan 40mg tablet, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Telmisartan 80mg tablet, QD in morning</description>
          </group>
          <group group_id="O5">
            <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
            <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O6">
            <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
            <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O7">
            <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
            <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O8">
            <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
            <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O9">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O10">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O11">
            <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
            <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O12">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O13">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O14">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O15">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O16">
            <title>Amlodipine 10 mg (A10)</title>
            <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects)</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="129"/>
                <count group_id="O4" value="132"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="123"/>
                <count group_id="O11" value="46"/>
                <count group_id="O12" value="143"/>
                <count group_id="O13" value="136"/>
                <count group_id="O14" value="48"/>
                <count group_id="O15" value="137"/>
                <count group_id="O16" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="1.2"/>
                    <measurement group_id="O2" value="-13.8" spread="1.3"/>
                    <measurement group_id="O3" value="-13.4" spread="0.7"/>
                    <measurement group_id="O4" value="-14" spread="0.7"/>
                    <measurement group_id="O5" value="-18.3" spread="1.2"/>
                    <measurement group_id="O6" value="-15.9" spread="1.2"/>
                    <measurement group_id="O7" value="-19.3" spread="1.3"/>
                    <measurement group_id="O8" value="-16.9" spread="1.2"/>
                    <measurement group_id="O9" value="-16.5" spread="0.7"/>
                    <measurement group_id="O10" value="-20.2" spread="0.7"/>
                    <measurement group_id="O11" value="-15.7" spread="1.2"/>
                    <measurement group_id="O12" value="-18.2" spread="0.7"/>
                    <measurement group_id="O13" value="-20.1" spread="0.7"/>
                    <measurement group_id="O14" value="-10.6" spread="1.2"/>
                    <measurement group_id="O15" value="-13.4" spread="0.7"/>
                    <measurement group_id="O16" value="-17.11" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
        <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC), excluding patients treated with placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Telmisartan 20mg tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Telmisartan 40mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Telmisartan 80mg tablet, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
            <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O5">
            <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
            <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O6">
            <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
            <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O7">
            <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
            <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O8">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O9">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O10">
            <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
            <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O11">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O12">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O13">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O14">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O15">
            <title>Amlodipine 10 mg (A10)</title>
            <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC), excluding patients treated with placebo</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="141"/>
                <count group_id="O9" value="123"/>
                <count group_id="O10" value="46"/>
                <count group_id="O11" value="143"/>
                <count group_id="O12" value="136"/>
                <count group_id="O13" value="48"/>
                <count group_id="O14" value="137"/>
                <count group_id="O15" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" spread="1.2"/>
                    <measurement group_id="O2" value="-13.4" spread="0.7"/>
                    <measurement group_id="O3" value="-14" spread="0.7"/>
                    <measurement group_id="O4" value="-18.3" spread="1.2"/>
                    <measurement group_id="O5" value="-15.9" spread="1.2"/>
                    <measurement group_id="O6" value="-19.3" spread="1.3"/>
                    <measurement group_id="O7" value="-16.9" spread="1.2"/>
                    <measurement group_id="O8" value="-16.5" spread="0.7"/>
                    <measurement group_id="O9" value="-20.2" spread="0.7"/>
                    <measurement group_id="O10" value="-15.7" spread="1.2"/>
                    <measurement group_id="O11" value="-18.2" spread="0.7"/>
                    <measurement group_id="O12" value="-20.1" spread="0.7"/>
                    <measurement group_id="O13" value="-10.6" spread="1.2"/>
                    <measurement group_id="O14" value="-13.4" spread="0.7"/>
                    <measurement group_id="O15" value="-17.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Systolic Blood Pressure (SBP)</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.</description>
        <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Telmisartan 20mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Telmisartan 40mg tablet, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Telmisartan 80mg tablet, QD in morning</description>
          </group>
          <group group_id="O5">
            <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
            <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O6">
            <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
            <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O7">
            <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
            <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O8">
            <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
            <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O9">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O10">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O11">
            <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
            <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O12">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O13">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O14">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O15">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O16">
            <title>Amlodipine 10 mg (A10)</title>
            <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Systolic Blood Pressure (SBP)</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="129"/>
                <count group_id="O4" value="132"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="141"/>
                <count group_id="O10" value="123"/>
                <count group_id="O11" value="46"/>
                <count group_id="O12" value="143"/>
                <count group_id="O13" value="136"/>
                <count group_id="O14" value="48"/>
                <count group_id="O15" value="137"/>
                <count group_id="O16" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.8"/>
                    <measurement group_id="O2" value="-15.1" spread="1.9"/>
                    <measurement group_id="O3" value="-14.6" spread="1.1"/>
                    <measurement group_id="O4" value="-14.3" spread="1.1"/>
                    <measurement group_id="O5" value="-18.8" spread="1.9"/>
                    <measurement group_id="O6" value="-21" spread="1.9"/>
                    <measurement group_id="O7" value="-24.4" spread="2"/>
                    <measurement group_id="O8" value="-21.9" spread="1.8"/>
                    <measurement group_id="O9" value="-21.8" spread="1.1"/>
                    <measurement group_id="O10" value="-24.7" spread="1.1"/>
                    <measurement group_id="O11" value="-17.4" spread="1.8"/>
                    <measurement group_id="O12" value="-22.1" spread="1"/>
                    <measurement group_id="O13" value="-26.4" spread="1.1"/>
                    <measurement group_id="O14" value="-11.4" spread="1.8"/>
                    <measurement group_id="O15" value="-15.4" spread="1.1"/>
                    <measurement group_id="O16" value="-20.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 8 Weeks in Standing Trough Cuff Mean DBP</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
        <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Telmisartan 20mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Telmisartan 40mg tablet, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Telmisartan 80mg tablet, QD in morning</description>
          </group>
          <group group_id="O5">
            <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
            <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O6">
            <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
            <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O7">
            <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
            <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O8">
            <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
            <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O9">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O10">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O11">
            <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
            <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O12">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O13">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O14">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O15">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O16">
            <title>Amlodipine 10 mg (A10)</title>
            <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 8 Weeks in Standing Trough Cuff Mean DBP</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="128"/>
                <count group_id="O4" value="129"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="139"/>
                <count group_id="O10" value="123"/>
                <count group_id="O11" value="46"/>
                <count group_id="O12" value="142"/>
                <count group_id="O13" value="134"/>
                <count group_id="O14" value="46"/>
                <count group_id="O15" value="137"/>
                <count group_id="O16" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="1.2"/>
                    <measurement group_id="O2" value="-10.4" spread="1.3"/>
                    <measurement group_id="O3" value="-10" spread="0.8"/>
                    <measurement group_id="O4" value="-11.1" spread="0.8"/>
                    <measurement group_id="O5" value="-14.9" spread="1.3"/>
                    <measurement group_id="O6" value="-13.1" spread="1.3"/>
                    <measurement group_id="O7" value="-16.9" spread="1.3"/>
                    <measurement group_id="O8" value="-15.8" spread="1.2"/>
                    <measurement group_id="O9" value="-13.6" spread="0.7"/>
                    <measurement group_id="O10" value="-18.4" spread="0.8"/>
                    <measurement group_id="O11" value="-13.4" spread="1.2"/>
                    <measurement group_id="O12" value="-16.2" spread="0.7"/>
                    <measurement group_id="O13" value="-19" spread="0.7"/>
                    <measurement group_id="O14" value="-8.1" spread="1.2"/>
                    <measurement group_id="O15" value="-11.3" spread="0.7"/>
                    <measurement group_id="O16" value="-14.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 8 Weeks in Standing Trough Cuff Mean SBP</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.</description>
        <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Telmisartan 20mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Telmisartan 40mg tablet, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Telmisartan 80mg tablet, QD in morning</description>
          </group>
          <group group_id="O5">
            <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
            <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O6">
            <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
            <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O7">
            <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
            <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O8">
            <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
            <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O9">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O10">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O11">
            <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
            <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O12">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O13">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O14">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O15">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O16">
            <title>Amlodipine 10 mg (A10)</title>
            <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 8 Weeks in Standing Trough Cuff Mean SBP</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="128"/>
                <count group_id="O4" value="129"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="47"/>
                <count group_id="O9" value="139"/>
                <count group_id="O10" value="123"/>
                <count group_id="O11" value="46"/>
                <count group_id="O12" value="142"/>
                <count group_id="O13" value="134"/>
                <count group_id="O14" value="46"/>
                <count group_id="O15" value="137"/>
                <count group_id="O16" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.9"/>
                    <measurement group_id="O2" value="-13.2" spread="2"/>
                    <measurement group_id="O3" value="-13.2" spread="1.1"/>
                    <measurement group_id="O4" value="-12.9" spread="1.1"/>
                    <measurement group_id="O5" value="-17.4" spread="1.9"/>
                    <measurement group_id="O6" value="-18.9" spread="1.9"/>
                    <measurement group_id="O7" value="-22.3" spread="2"/>
                    <measurement group_id="O8" value="-20.3" spread="1.8"/>
                    <measurement group_id="O9" value="-20" spread="1.1"/>
                    <measurement group_id="O10" value="-22.8" spread="1.1"/>
                    <measurement group_id="O11" value="-17.4" spread="1.9"/>
                    <measurement group_id="O12" value="-21.2" spread="1.1"/>
                    <measurement group_id="O13" value="-24.9" spread="1.1"/>
                    <measurement group_id="O14" value="-9.1" spread="1.9"/>
                    <measurement group_id="O15" value="-14.7" spread="1.1"/>
                    <measurement group_id="O16" value="-19.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline at 2,4,6,and 8 Weeks in Seated Trough Cuff DBP</title>
        <description>Observed results for key combination therapies</description>
        <time_frame>Baseline to nominal week over the trial</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 2,4,6,and 8 Weeks in Seated Trough Cuff DBP</title>
          <description>Observed results for key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="139"/>
                <count group_id="O4" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.5" spread="8.76"/>
                    <measurement group_id="O2" value="-14.4" spread="7.62"/>
                    <measurement group_id="O3" value="-15.3" spread="7.87"/>
                    <measurement group_id="O4" value="-14.6" spread="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=133, 115, 135, 129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0" spread="7.24"/>
                    <measurement group_id="O2" value="-18.1" spread="8.52"/>
                    <measurement group_id="O3" value="-17.2" spread="7.56"/>
                    <measurement group_id="O4" value="-18.8" spread="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=134, 118, 131, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.1" spread="8.59"/>
                    <measurement group_id="O2" value="-19.0" spread="8.30"/>
                    <measurement group_id="O3" value="-18.0" spread="8.02"/>
                    <measurement group_id="O4" value="-20.0" spread="8.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (N=133, 112, 132, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.3" spread="7.42"/>
                    <measurement group_id="O2" value="-19.5" spread="8.03"/>
                    <measurement group_id="O3" value="-18.3" spread="8.28"/>
                    <measurement group_id="O4" value="-20.0" spread="7.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP Control</title>
        <description>DBP control is defined as DBP &lt; 90 mmHg - key combination therapies</description>
        <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>DBP Control</title>
          <description>DBP control is defined as DBP &lt; 90 mmHg - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6"/>
                    <measurement group_id="O2" value="82.1"/>
                    <measurement group_id="O3" value="74.8"/>
                    <measurement group_id="O4" value="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP Response</title>
        <description>DBP response is defined as DBP &lt; 90 mmHg or a reduction of DBP of &gt;= 10 mmHg - key combination therapies</description>
        <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>DBP Response</title>
          <description>DBP response is defined as DBP &lt; 90 mmHg or a reduction of DBP of &gt;= 10 mmHg - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.9"/>
                    <measurement group_id="O2" value="91.9"/>
                    <measurement group_id="O3" value="88.8"/>
                    <measurement group_id="O4" value="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Response</title>
        <description>SBP Response is defined as SBP &lt; 140 mmHg or a reduction of SBP of &gt;= 10 mmHg - key combination therapies</description>
        <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Response</title>
          <description>SBP Response is defined as SBP &lt; 140 mmHg or a reduction of SBP of &gt;= 10 mmHg - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5"/>
                    <measurement group_id="O2" value="96.7"/>
                    <measurement group_id="O3" value="87.4"/>
                    <measurement group_id="O4" value="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>BP Control</title>
        <description>Percentage of responders (SBP&lt;140 mmHg and DBP&lt;90 mmHg) for all patients - key combination therapies</description>
        <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic and systolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control</title>
          <description>Percentage of responders (SBP&lt;140 mmHg and DBP&lt;90 mmHg) for all patients - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic and systolic blood pressure measurement following treatment with target therapy (FAS-TC).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9"/>
                    <measurement group_id="O2" value="75.6"/>
                    <measurement group_id="O3" value="65.7"/>
                    <measurement group_id="O4" value="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Normality</title>
        <description>No: Mean seated SBP &gt;=140 and/or mean seated DBP &gt;=90 mmHg at trough High normal: mean seated SBP &gt;=130 and &lt;140 mmHg and mean seated DBP &gt;=85 and &lt;90 mmHg at trough Normal: mean seated SBP &gt;=120 and &lt;130 mmHg and mean seated DBP &gt;=80 and &lt;85 mmHg at trough Optimal: mean seated SBP &lt; 120 mmHg and mean seated DBP &lt;80 mmHg at trough
- key combination therapies</description>
        <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic and Diastolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>BP Normality</title>
          <description>No: Mean seated SBP &gt;=140 and/or mean seated DBP &gt;=90 mmHg at trough High normal: mean seated SBP &gt;=130 and &lt;140 mmHg and mean seated DBP &gt;=85 and &lt;90 mmHg at trough Normal: mean seated SBP &gt;=120 and &lt;130 mmHg and mean seated DBP &gt;=80 and &lt;85 mmHg at trough Optimal: mean seated SBP &lt; 120 mmHg and mean seated DBP &lt;80 mmHg at trough
- key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic and Diastolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No (SBP&gt;=140 and/or DBP&gt;=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="34.3"/>
                    <measurement group_id="O4" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Normal (140&gt;SBP&gt;=130 and 90&gt;DBP&gt;=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="30.1"/>
                    <measurement group_id="O3" value="30.1"/>
                    <measurement group_id="O4" value="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (130&gt;SBP&gt;=120 and 85&gt;DBP&gt;=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="32.5"/>
                    <measurement group_id="O3" value="25.9"/>
                    <measurement group_id="O4" value="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Optimal (SBP&lt;120 and DBP&lt;80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9.8"/>
                    <measurement group_id="O4" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP</title>
        <description>Observed results - key combination therapies</description>
        <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP</title>
          <description>Observed results - key combination therapies</description>
          <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="9.5"/>
                    <measurement group_id="O2" value="-15.4" spread="11.6"/>
                    <measurement group_id="O3" value="-12.7" spread="9.9"/>
                    <measurement group_id="O4" value="-13.4" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="11.7"/>
                    <measurement group_id="O2" value="-15" spread="12.2"/>
                    <measurement group_id="O3" value="-13.4" spread="9.5"/>
                    <measurement group_id="O4" value="-14.6" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="13.2"/>
                    <measurement group_id="O2" value="-14.1" spread="12.6"/>
                    <measurement group_id="O3" value="-14.8" spread="11.6"/>
                    <measurement group_id="O4" value="-15.4" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" spread="11.8"/>
                    <measurement group_id="O2" value="-16.5" spread="13.2"/>
                    <measurement group_id="O3" value="-15.6" spread="11.7"/>
                    <measurement group_id="O4" value="-15.8" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" spread="11"/>
                    <measurement group_id="O2" value="-14.1" spread="14.4"/>
                    <measurement group_id="O3" value="-16.3" spread="14.3"/>
                    <measurement group_id="O4" value="-15.7" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="11.6"/>
                    <measurement group_id="O2" value="-14.5" spread="12.4"/>
                    <measurement group_id="O3" value="-14.6" spread="9.9"/>
                    <measurement group_id="O4" value="-16.4" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="10.2"/>
                    <measurement group_id="O2" value="-15.6" spread="13.9"/>
                    <measurement group_id="O3" value="-12.9" spread="10.4"/>
                    <measurement group_id="O4" value="-15.7" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="12.3"/>
                    <measurement group_id="O2" value="-17.4" spread="13.6"/>
                    <measurement group_id="O3" value="-12.7" spread="13.6"/>
                    <measurement group_id="O4" value="-17.1" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" spread="10.3"/>
                    <measurement group_id="O2" value="-15.7" spread="14.4"/>
                    <measurement group_id="O3" value="-14.3" spread="14.3"/>
                    <measurement group_id="O4" value="-17.2" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="10.3"/>
                    <measurement group_id="O2" value="-13.8" spread="13.5"/>
                    <measurement group_id="O3" value="-14.7" spread="15.7"/>
                    <measurement group_id="O4" value="-18.5" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="12.9"/>
                    <measurement group_id="O2" value="-14.4" spread="11.9"/>
                    <measurement group_id="O3" value="-15.1" spread="13.1"/>
                    <measurement group_id="O4" value="-16.1" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" spread="11.3"/>
                    <measurement group_id="O2" value="-13.3" spread="12.9"/>
                    <measurement group_id="O3" value="-12.5" spread="14.8"/>
                    <measurement group_id="O4" value="-15.7" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="11.7"/>
                    <measurement group_id="O2" value="-14.7" spread="14.3"/>
                    <measurement group_id="O3" value="-14.1" spread="13.5"/>
                    <measurement group_id="O4" value="-15.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="13.2"/>
                    <measurement group_id="O2" value="-14.8" spread="14.1"/>
                    <measurement group_id="O3" value="-13.4" spread="13.4"/>
                    <measurement group_id="O4" value="-11" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="16"/>
                    <measurement group_id="O2" value="-11.5" spread="14.3"/>
                    <measurement group_id="O3" value="-11.9" spread="14.8"/>
                    <measurement group_id="O4" value="-10" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="15"/>
                    <measurement group_id="O2" value="-10.3" spread="15.4"/>
                    <measurement group_id="O3" value="-11.3" spread="12"/>
                    <measurement group_id="O4" value="-12.2" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="13.7"/>
                    <measurement group_id="O2" value="-10.4" spread="14.4"/>
                    <measurement group_id="O3" value="-11.2" spread="12.5"/>
                    <measurement group_id="O4" value="-11.5" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="15"/>
                    <measurement group_id="O2" value="-9.9" spread="12.4"/>
                    <measurement group_id="O3" value="-10.3" spread="12.3"/>
                    <measurement group_id="O4" value="-12.2" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="10.9"/>
                    <measurement group_id="O2" value="-10.5" spread="13.7"/>
                    <measurement group_id="O3" value="-11.9" spread="10.4"/>
                    <measurement group_id="O4" value="-13.2" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" spread="11.9"/>
                    <measurement group_id="O2" value="-9.9" spread="12.4"/>
                    <measurement group_id="O3" value="-12.6" spread="11.1"/>
                    <measurement group_id="O4" value="-15.9" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="13"/>
                    <measurement group_id="O2" value="-8.9" spread="13.2"/>
                    <measurement group_id="O3" value="-8.5" spread="12.7"/>
                    <measurement group_id="O4" value="-14.8" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" spread="12.6"/>
                    <measurement group_id="O2" value="-9.8" spread="13.7"/>
                    <measurement group_id="O3" value="-9.7" spread="12.9"/>
                    <measurement group_id="O4" value="-15.4" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="11.3"/>
                    <measurement group_id="O2" value="-13.3" spread="13.4"/>
                    <measurement group_id="O3" value="-9.9" spread="12.2"/>
                    <measurement group_id="O4" value="-14.6" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" spread="9.5"/>
                    <measurement group_id="O2" value="-12.6" spread="11.5"/>
                    <measurement group_id="O3" value="-12" spread="13.1"/>
                    <measurement group_id="O4" value="-13.1" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ABPM Hourly Mean (Relative to Dosing) SBP</title>
        <description>Observed results - key combination therapies</description>
        <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ABPM Hourly Mean (Relative to Dosing) SBP</title>
          <description>Observed results - key combination therapies</description>
          <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" spread="12.9"/>
                    <measurement group_id="O2" value="-20.2" spread="16.5"/>
                    <measurement group_id="O3" value="-19.1" spread="13.4"/>
                    <measurement group_id="O4" value="-17.5" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" spread="16.5"/>
                    <measurement group_id="O2" value="-22.0" spread="17.9"/>
                    <measurement group_id="O3" value="-20.5" spread="16.6"/>
                    <measurement group_id="O4" value="-21.9" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3" spread="16.1"/>
                    <measurement group_id="O2" value="-17.9" spread="18.9"/>
                    <measurement group_id="O3" value="-21.1" spread="17.8"/>
                    <measurement group_id="O4" value="-22.4" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.0" spread="16.9"/>
                    <measurement group_id="O2" value="-24.4" spread="20.6"/>
                    <measurement group_id="O3" value="-22.5" spread="16.5"/>
                    <measurement group_id="O4" value="-23.8" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.3" spread="13.6"/>
                    <measurement group_id="O2" value="-21.1" spread="19.8"/>
                    <measurement group_id="O3" value="-25.3" spread="18.1"/>
                    <measurement group_id="O4" value="-24.0" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.1" spread="14.0"/>
                    <measurement group_id="O2" value="-22.6" spread="14.9"/>
                    <measurement group_id="O3" value="-21.6" spread="15.9"/>
                    <measurement group_id="O4" value="-24.6" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.8" spread="14.5"/>
                    <measurement group_id="O2" value="-24.3" spread="19.5"/>
                    <measurement group_id="O3" value="-19.9" spread="17.7"/>
                    <measurement group_id="O4" value="-22.4" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.8" spread="17.1"/>
                    <measurement group_id="O2" value="-24.1" spread="20.8"/>
                    <measurement group_id="O3" value="-20.3" spread="18.6"/>
                    <measurement group_id="O4" value="-21.8" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.3" spread="15.6"/>
                    <measurement group_id="O2" value="-24.9" spread="20.0"/>
                    <measurement group_id="O3" value="-22.0" spread="19.2"/>
                    <measurement group_id="O4" value="-25.6" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.0" spread="16.0"/>
                    <measurement group_id="O2" value="-22.9" spread="19.2"/>
                    <measurement group_id="O3" value="-22.5" spread="19.3"/>
                    <measurement group_id="O4" value="-26.8" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" spread="17.4"/>
                    <measurement group_id="O2" value="-20.9" spread="19.8"/>
                    <measurement group_id="O3" value="-23.2" spread="16.7"/>
                    <measurement group_id="O4" value="-24.9" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.4" spread="16.8"/>
                    <measurement group_id="O2" value="-20.3" spread="19.5"/>
                    <measurement group_id="O3" value="-19.7" spread="19.1"/>
                    <measurement group_id="O4" value="-25.0" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.5" spread="16.9"/>
                    <measurement group_id="O2" value="-21.7" spread="23.5"/>
                    <measurement group_id="O3" value="-22.7" spread="18.3"/>
                    <measurement group_id="O4" value="-24.7" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="17.6"/>
                    <measurement group_id="O2" value="-21.6" spread="20.8"/>
                    <measurement group_id="O3" value="-21.7" spread="19.2"/>
                    <measurement group_id="O4" value="-20.2" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.7" spread="18.1"/>
                    <measurement group_id="O2" value="-19.4" spread="20.5"/>
                    <measurement group_id="O3" value="-19.0" spread="20.2"/>
                    <measurement group_id="O4" value="-18.9" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.0" spread="16.9"/>
                    <measurement group_id="O2" value="-17.7" spread="20.0"/>
                    <measurement group_id="O3" value="-18.0" spread="16.0"/>
                    <measurement group_id="O4" value="-19.8" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3" spread="17.3"/>
                    <measurement group_id="O2" value="-17.9" spread="20.3"/>
                    <measurement group_id="O3" value="-14.7" spread="15.8"/>
                    <measurement group_id="O4" value="-19.1" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.5" spread="18.6"/>
                    <measurement group_id="O2" value="-17.4" spread="16.4"/>
                    <measurement group_id="O3" value="-15.1" spread="16.8"/>
                    <measurement group_id="O4" value="-19.6" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.5" spread="15.6"/>
                    <measurement group_id="O2" value="-19.7" spread="18.4"/>
                    <measurement group_id="O3" value="-16.9" spread="15.3"/>
                    <measurement group_id="O4" value="-20.9" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.8" spread="16.4"/>
                    <measurement group_id="O2" value="-18.0" spread="17.4"/>
                    <measurement group_id="O3" value="-16.5" spread="15.3"/>
                    <measurement group_id="O4" value="-24.4" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.5" spread="15.9"/>
                    <measurement group_id="O2" value="-17.8" spread="17.6"/>
                    <measurement group_id="O3" value="-15.7" spread="16.4"/>
                    <measurement group_id="O4" value="-22.7" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.2" spread="15.9"/>
                    <measurement group_id="O2" value="-15.7" spread="17.0"/>
                    <measurement group_id="O3" value="-15.5" spread="18.7"/>
                    <measurement group_id="O4" value="-23.8" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" spread="14.6"/>
                    <measurement group_id="O2" value="-18.9" spread="16.1"/>
                    <measurement group_id="O3" value="-16.5" spread="19.1"/>
                    <measurement group_id="O4" value="-22.4" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" spread="14.9"/>
                    <measurement group_id="O2" value="-20.7" spread="16.3"/>
                    <measurement group_id="O3" value="-18.5" spread="18.1"/>
                    <measurement group_id="O4" value="-19.9" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ABPM 24-hour Mean DBP</title>
        <description>Observed results - key combination therapies</description>
        <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ABPM 24-hour Mean DBP</title>
          <description>Observed results - key combination therapies</description>
          <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" spread="7.2"/>
                    <measurement group_id="O2" value="-13.2" spread="7.7"/>
                    <measurement group_id="O3" value="-12.8" spread="7.4"/>
                    <measurement group_id="O4" value="-14.6" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ABPM 24-hour Mean SBP</title>
        <description>Observed results - key combination therapies</description>
        <time_frame>End-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ABPM 24-hour Mean SBP</title>
          <description>Observed results - key combination therapies</description>
          <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.3" spread="10.4"/>
                    <measurement group_id="O2" value="-20.5" spread="13.9"/>
                    <measurement group_id="O3" value="-19.5" spread="11.6"/>
                    <measurement group_id="O4" value="-22.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Orthostatic Change in Trough Cuff Mean DBP</title>
        <description>Calculated as seated minus standing for all patients - key combination therapies</description>
        <time_frame>Week 8</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Orthostatic Change in Trough Cuff Mean DBP</title>
          <description>Calculated as seated minus standing for all patients - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="5.7"/>
                    <measurement group_id="O2" value="1.7" spread="5.4"/>
                    <measurement group_id="O3" value="2" spread="5.4"/>
                    <measurement group_id="O4" value="1.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Orthostatic Change in Trough Cuff Mean SBP</title>
        <description>Calculated as seated minus standing for all patients - key combination therapies</description>
        <time_frame>Week 8</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Orthostatic Change in Trough Cuff Mean SBP</title>
          <description>Calculated as seated minus standing for all patients - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy (FAS-TC)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="7.5"/>
                    <measurement group_id="O2" value="0.6" spread="8"/>
                    <measurement group_id="O3" value="0.9" spread="7.5"/>
                    <measurement group_id="O4" value="0.8" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Seated Trough Cuff Mean DBP (Observed Telmisartan Effect)</title>
        <description>Observed results</description>
        <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 0 mg (T0)</title>
            <description>Overall: including Pl, A2.5, A5, and A10 treated groups</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Overall: including all treatment groups involving T20</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Overall: including all treatment groups involving T40</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Overall: including all treatment groups involving T80</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Trough Cuff Mean DBP (Observed Telmisartan Effect)</title>
          <description>Observed results</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="334"/>
                <count group_id="O4" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" spread="9"/>
                    <measurement group_id="O2" value="-16.8" spread="8"/>
                    <measurement group_id="O3" value="-16.9" spread="8.9"/>
                    <measurement group_id="O4" value="-17.7" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
        <time_frame>Baseline to end-of-study (up to 8 weeks) visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Amlodipine 10 mg (A10)</title>
            <description>monotherapy (A5 titrated to A10)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects)</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="334"/>
                <count group_id="O4" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.7" spread="0.5"/>
                    <measurement group_id="O2" value="-17.3" spread="0.7"/>
                    <measurement group_id="O3" value="-17.3" spread="0.5"/>
                    <measurement group_id="O4" value="-18" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects)</title>
        <description>Observed results</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 0 mg (A0) - Overall</title>
            <description>Overall: including Pl, T20, T40, and T80 treatment groups</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 2.5 mg (A2.5) - Overall</title>
            <description>Overall: including all treatment groups involving A2.5</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg (A5) - Overall</title>
            <description>Overall: including all treatment groups involving A5</description>
          </group>
          <group group_id="O4">
            <title>Amlodipine 10 mg (A10) - Overall</title>
            <description>Overall: including all treatment groups involving A10</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects)</title>
          <description>Observed results</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="349"/>
                <count group_id="O4" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.7" spread="10.1"/>
                    <measurement group_id="O2" value="-16" spread="8.4"/>
                    <measurement group_id="O3" value="-16.3" spread="8.3"/>
                    <measurement group_id="O4" value="-19.2" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 0 mg (A0) - Overall</title>
            <description>Overall: including Pl, T20, T40, and T80 treatment groups</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine 2.5 mg (A2.5) - Overall</title>
            <description>Overall: including all treatment groups involving A2.5</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 5 mg (A5) - Overall</title>
            <description>Overall: including all treatment groups involving A5</description>
          </group>
          <group group_id="O4">
            <title>Amlodipine 10 mg (A10) - Overall</title>
            <description>Overall: including all treatment groups involving A10</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects)</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="349"/>
                <count group_id="O4" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" spread="0.5"/>
                    <measurement group_id="O2" value="-16.4" spread="0.7"/>
                    <measurement group_id="O3" value="-16.7" spread="0.5"/>
                    <measurement group_id="O4" value="-19.7" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Seated Trough Cuff Mean DBP (Observed Treatment Effects)</title>
        <description>Observed results</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Telmisartan 20mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Telmisartan 40mg tablet, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Telmisartan 80mg tablet, QD in morning</description>
          </group>
          <group group_id="O5">
            <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
            <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O6">
            <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
            <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O7">
            <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
            <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O8">
            <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
            <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O9">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O10">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O11">
            <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
            <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O12">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O13">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O14">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O15">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O16">
            <title>Amlodipine 10 mg (A10)</title>
            <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Trough Cuff Mean DBP (Observed Treatment Effects)</title>
          <description>Observed results</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="108"/>
                <count group_id="O10" value="96"/>
                <count group_id="O11" value="36"/>
                <count group_id="O12" value="106"/>
                <count group_id="O13" value="100"/>
                <count group_id="O14" value="37"/>
                <count group_id="O15" value="101"/>
                <count group_id="O16" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="10.1"/>
                    <measurement group_id="O2" value="-13.9" spread="9.4"/>
                    <measurement group_id="O3" value="-13.8" spread="10.2"/>
                    <measurement group_id="O4" value="-13.9" spread="9.2"/>
                    <measurement group_id="O5" value="-18.4" spread="7.9"/>
                    <measurement group_id="O6" value="-15.8" spread="6.4"/>
                    <measurement group_id="O7" value="-19.5" spread="7.2"/>
                    <measurement group_id="O8" value="-18.7" spread="7.9"/>
                    <measurement group_id="O9" value="-16.8" spread="7.5"/>
                    <measurement group_id="O10" value="-19.6" spread="8.3"/>
                    <measurement group_id="O11" value="-16.3" spread="7.7"/>
                    <measurement group_id="O12" value="-18.8" spread="9"/>
                    <measurement group_id="O13" value="-20.4" spread="7.3"/>
                    <measurement group_id="O14" value="-11.4" spread="8.3"/>
                    <measurement group_id="O15" value="-13.1" spread="8.1"/>
                    <measurement group_id="O16" value="-17.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects)</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Telmisartan 20mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Telmisartan 40mg tablet, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Telmisartan 80mg tablet, QD in morning</description>
          </group>
          <group group_id="O5">
            <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
            <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O6">
            <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
            <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O7">
            <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
            <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O8">
            <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
            <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O9">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O10">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O11">
            <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
            <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O12">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O13">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O14">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O15">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O16">
            <title>Amlodipine 10 mg (A10)</title>
            <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects)</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="108"/>
                <count group_id="O10" value="96"/>
                <count group_id="O11" value="36"/>
                <count group_id="O12" value="106"/>
                <count group_id="O13" value="100"/>
                <count group_id="O14" value="37"/>
                <count group_id="O15" value="101"/>
                <count group_id="O16" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="1.4"/>
                    <measurement group_id="O2" value="-14.4" spread="1.4"/>
                    <measurement group_id="O3" value="-14.2" spread="0.8"/>
                    <measurement group_id="O4" value="-14.1" spread="0.9"/>
                    <measurement group_id="O5" value="-18.9" spread="1.4"/>
                    <measurement group_id="O6" value="-15.9" spread="1.4"/>
                    <measurement group_id="O7" value="-19.7" spread="1.6"/>
                    <measurement group_id="O8" value="-18.8" spread="1.5"/>
                    <measurement group_id="O9" value="-17.2" spread="0.8"/>
                    <measurement group_id="O10" value="-20.1" spread="0.8"/>
                    <measurement group_id="O11" value="-16.6" spread="1.4"/>
                    <measurement group_id="O12" value="-19.1" spread="0.8"/>
                    <measurement group_id="O13" value="-21" spread="0.8"/>
                    <measurement group_id="O14" value="-11.7" spread="1.4"/>
                    <measurement group_id="O15" value="-13.3" spread="0.8"/>
                    <measurement group_id="O16" value="-17.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as moderate or severe hypertension at baseline (FAS-TC-MS), excluding patients treated with placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Telmisartan 20mg tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Telmisartan 40mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Telmisartan 80mg tablet, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
            <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O5">
            <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
            <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O6">
            <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
            <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O7">
            <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
            <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O8">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O9">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O10">
            <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
            <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O11">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O12">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O13">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O14">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O15">
            <title>Amlodipine 10 mg (A10)</title>
            <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects, Excluding Pl)</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as moderate or severe hypertension at baseline (FAS-TC-MS), excluding patients treated with placebo</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="28"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="108"/>
                <count group_id="O9" value="96"/>
                <count group_id="O10" value="36"/>
                <count group_id="O11" value="106"/>
                <count group_id="O12" value="100"/>
                <count group_id="O13" value="37"/>
                <count group_id="O14" value="101"/>
                <count group_id="O15" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.5" spread="1.4"/>
                    <measurement group_id="O2" value="-14.2" spread="0.8"/>
                    <measurement group_id="O3" value="-14.1" spread="0.9"/>
                    <measurement group_id="O4" value="-18.9" spread="1.4"/>
                    <measurement group_id="O5" value="-15.9" spread="1.4"/>
                    <measurement group_id="O6" value="-19.7" spread="1.5"/>
                    <measurement group_id="O7" value="-18.8" spread="1.5"/>
                    <measurement group_id="O8" value="-17.2" spread="0.8"/>
                    <measurement group_id="O9" value="-20.1" spread="0.8"/>
                    <measurement group_id="O10" value="-16.6" spread="1.4"/>
                    <measurement group_id="O11" value="-19.1" spread="0.8"/>
                    <measurement group_id="O12" value="-21" spread="0.8"/>
                    <measurement group_id="O13" value="-11.7" spread="1.3"/>
                    <measurement group_id="O14" value="-13.3" spread="0.8"/>
                    <measurement group_id="O15" value="-17.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Seated Trough Pulse Rate</title>
        <description>Observed results for all patients - key combination therapies</description>
        <time_frame>End-of-study visit (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff Pulse Rate measurements included all treated patients that had at least one Pulse Rate measurement following treatment with target therapy (FAS-TC)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Trough Pulse Rate</title>
          <description>Observed results for all patients - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff Pulse Rate measurements included all treated patients that had at least one Pulse Rate measurement following treatment with target therapy (FAS-TC)</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="8.8"/>
                    <measurement group_id="O2" value="0" spread="9.5"/>
                    <measurement group_id="O3" value="2.4" spread="9.3"/>
                    <measurement group_id="O4" value="-1.5" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Seated Trough Cuff Mean SBP</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Telmisartan 20mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Telmisartan 40mg tablet, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Telmisartan 80mg tablet, QD in morning</description>
          </group>
          <group group_id="O5">
            <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
            <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O6">
            <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
            <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O7">
            <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
            <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O8">
            <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
            <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O9">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O10">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O11">
            <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
            <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O12">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O13">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O14">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O15">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O16">
            <title>Amlodipine 10 mg (A10)</title>
            <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Trough Cuff Mean SBP</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="108"/>
                <count group_id="O10" value="96"/>
                <count group_id="O11" value="36"/>
                <count group_id="O12" value="106"/>
                <count group_id="O13" value="100"/>
                <count group_id="O14" value="37"/>
                <count group_id="O15" value="101"/>
                <count group_id="O16" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="2.1"/>
                    <measurement group_id="O2" value="-15.6" spread="2.1"/>
                    <measurement group_id="O3" value="-15.4" spread="1.2"/>
                    <measurement group_id="O4" value="-15.4" spread="1.3"/>
                    <measurement group_id="O5" value="-19" spread="2.1"/>
                    <measurement group_id="O6" value="-22.1" spread="2.1"/>
                    <measurement group_id="O7" value="-25.2" spread="2.3"/>
                    <measurement group_id="O8" value="-23.2" spread="2.2"/>
                    <measurement group_id="O9" value="-22.2" spread="1.2"/>
                    <measurement group_id="O10" value="-25.3" spread="1.3"/>
                    <measurement group_id="O11" value="-17.4" spread="2"/>
                    <measurement group_id="O12" value="-22.5" spread="1.2"/>
                    <measurement group_id="O13" value="-26.5" spread="1.2"/>
                    <measurement group_id="O14" value="-12.4" spread="2"/>
                    <measurement group_id="O15" value="-14.8" spread="1.2"/>
                    <measurement group_id="O16" value="-21" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Standing Trough Cuff Mean DBP</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Telmisartan 20mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Telmisartan 40mg tablet, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Telmisartan 80mg tablet, QD in morning</description>
          </group>
          <group group_id="O5">
            <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
            <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O6">
            <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
            <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O7">
            <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
            <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O8">
            <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
            <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O9">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O10">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O11">
            <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
            <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O12">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O13">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O14">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O15">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O16">
            <title>Amlodipine 10 mg (A10)</title>
            <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Standing Trough Cuff Mean DBP</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline DBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="107"/>
                <count group_id="O10" value="96"/>
                <count group_id="O11" value="36"/>
                <count group_id="O12" value="105"/>
                <count group_id="O13" value="100"/>
                <count group_id="O14" value="35"/>
                <count group_id="O15" value="101"/>
                <count group_id="O16" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="1.4"/>
                    <measurement group_id="O2" value="-11.7" spread="1.5"/>
                    <measurement group_id="O3" value="-10.9" spread="0.9"/>
                    <measurement group_id="O4" value="-11.3" spread="0.9"/>
                    <measurement group_id="O5" value="-15.1" spread="1.4"/>
                    <measurement group_id="O6" value="-13.3" spread="1.4"/>
                    <measurement group_id="O7" value="-17.6" spread="1.6"/>
                    <measurement group_id="O8" value="-17.5" spread="1.5"/>
                    <measurement group_id="O9" value="-14.2" spread="0.8"/>
                    <measurement group_id="O10" value="-18" spread="0.9"/>
                    <measurement group_id="O11" value="-14.5" spread="1.4"/>
                    <measurement group_id="O12" value="-17.3" spread="0.8"/>
                    <measurement group_id="O13" value="-19.2" spread="0.8"/>
                    <measurement group_id="O14" value="-8" spread="1.4"/>
                    <measurement group_id="O15" value="-11" spread="0.8"/>
                    <measurement group_id="O16" value="-15.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Seated Trough Cuff DBP</title>
        <description>Observed results for mod-sev patients - key combination therapies</description>
        <time_frame>Nominal week over the trial</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Trough Cuff DBP</title>
          <description>Observed results for mod-sev patients - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7" spread="8.9"/>
                    <measurement group_id="O2" value="-14.7" spread="7.8"/>
                    <measurement group_id="O3" value="-16.1" spread="7.9"/>
                    <measurement group_id="O4" value="-14.9" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (N=102, 90, 102, 96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.5" spread="6.8"/>
                    <measurement group_id="O2" value="-18.2" spread="9.2"/>
                    <measurement group_id="O3" value="-17.8" spread="7.6"/>
                    <measurement group_id="O4" value="-19.2" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (N=102, 92, 98, 96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.9" spread="7.8"/>
                    <measurement group_id="O2" value="-19.7" spread="8.7"/>
                    <measurement group_id="O3" value="-18.9" spread="8.2"/>
                    <measurement group_id="O4" value="-19.5" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (N=102, 87, 99, 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.1" spread="7.4"/>
                    <measurement group_id="O2" value="-19.4" spread="8.5"/>
                    <measurement group_id="O3" value="-19.3" spread="8.7"/>
                    <measurement group_id="O4" value="-21.1" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Standing Trough Cuff Mean SBP</title>
        <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 20 mg (T20)</title>
            <description>Telmisartan 20mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40 mg (T40)</title>
            <description>Telmisartan 40mg tablet, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg (T80)</title>
            <description>Telmisartan 80mg tablet, QD in morning</description>
          </group>
          <group group_id="O5">
            <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
            <description>T20mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O6">
            <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
            <description>T20mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O7">
            <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
            <description>T20mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O8">
            <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
            <description>T40mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O9">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O10">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O11">
            <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
            <description>T80mg tab plus encapsulated A2.5mg capsule, QD in morning</description>
          </group>
          <group group_id="O12">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O13">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O14">
            <title>Amlodipine 2.5 mg (A2.5)</title>
            <description>encapsulated Amlodipine 2.5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O15">
            <title>Amlodipine 5 mg (A5)</title>
            <description>encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
          <group group_id="O16">
            <title>Amlodipine 10 mg (A10)</title>
            <description>2 encapsulated Amlodipine 5 mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Standing Trough Cuff Mean SBP</title>
          <description>Results stem from an ANCOVA including the main effects of treatment with telmisartan, treatment with amlodipine, and country/region with baseline SBP included as a covariate.</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="107"/>
                <count group_id="O10" value="96"/>
                <count group_id="O11" value="36"/>
                <count group_id="O12" value="105"/>
                <count group_id="O13" value="100"/>
                <count group_id="O14" value="35"/>
                <count group_id="O15" value="101"/>
                <count group_id="O16" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="2.1"/>
                    <measurement group_id="O2" value="-13.7" spread="2.1"/>
                    <measurement group_id="O3" value="-13.6" spread="1.2"/>
                    <measurement group_id="O4" value="-14" spread="1.3"/>
                    <measurement group_id="O5" value="-16.2" spread="2.1"/>
                    <measurement group_id="O6" value="-19.4" spread="2.1"/>
                    <measurement group_id="O7" value="-23.2" spread="2.3"/>
                    <measurement group_id="O8" value="-21.8" spread="2.2"/>
                    <measurement group_id="O9" value="-20.4" spread="1.2"/>
                    <measurement group_id="O10" value="-22.8" spread="1.3"/>
                    <measurement group_id="O11" value="-16.3" spread="2"/>
                    <measurement group_id="O12" value="-21.9" spread="1.2"/>
                    <measurement group_id="O13" value="-24.3" spread="1.2"/>
                    <measurement group_id="O14" value="-10.1" spread="2.1"/>
                    <measurement group_id="O15" value="-13.2" spread="1.2"/>
                    <measurement group_id="O16" value="-19.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP Control</title>
        <description>DBP control is defined as DBP &lt; 90 mmHg - key combination therapies</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>DBP Control</title>
          <description>DBP control is defined as DBP &lt; 90 mmHg - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4"/>
                    <measurement group_id="O2" value="77.1"/>
                    <measurement group_id="O3" value="68.9"/>
                    <measurement group_id="O4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DBP Response</title>
        <description>DBP response is defined as DBP &lt; 90 mmHg or a reduction of DBP of &gt;= 10 mmHg - key combination therapies</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>DBP Response</title>
          <description>DBP response is defined as DBP &lt; 90 mmHg or a reduction of DBP of &gt;= 10 mmHg - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Diastolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5"/>
                    <measurement group_id="O2" value="89.6"/>
                    <measurement group_id="O3" value="87.7"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>BP Control</title>
        <description>Responders SBP&lt;10 mmHg and DBP&lt;90 mmHg) for mod-sev patients - key combination therapies</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic and systolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>BP Control</title>
          <description>Responders SBP&lt;10 mmHg and DBP&lt;90 mmHg) for mod-sev patients - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic and systolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7"/>
                    <measurement group_id="O2" value="70.8"/>
                    <measurement group_id="O3" value="58.5"/>
                    <measurement group_id="O4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Response</title>
        <description>SBP Response is defined as SBP &lt; 140 mmHg or a reduction of SBP of &gt;= 10 mmHg - key combination therapies</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Response</title>
          <description>SBP Response is defined as SBP &lt; 140 mmHg or a reduction of SBP of &gt;= 10 mmHg - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                    <measurement group_id="O2" value="96.9"/>
                    <measurement group_id="O3" value="84.9"/>
                    <measurement group_id="O4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BP Normality</title>
        <description>No: Mean seated SBP &gt;=140 and/or mean seated DBP &gt;=90 mmHg at trough High normal: mean seated SBP &gt;=130 and &lt;140 mmHg and mean seated DBP &gt;=85 and &lt;90 mmHg at trough Normal: mean seated SBP &gt;=120 and &lt;130 mmHg and mean seated DBP &gt;=80 and &lt;85 mmHg at trough Optimal: mean seated SBP &lt; 120 mmHg and mean seated DBP &lt;80 mmHg at trough
- key combination therapies</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic and Diastolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>BP Normality</title>
          <description>No: Mean seated SBP &gt;=140 and/or mean seated DBP &gt;=90 mmHg at trough High normal: mean seated SBP &gt;=130 and &lt;140 mmHg and mean seated DBP &gt;=85 and &lt;90 mmHg at trough Normal: mean seated SBP &gt;=120 and &lt;130 mmHg and mean seated DBP &gt;=80 and &lt;85 mmHg at trough Optimal: mean seated SBP &lt; 120 mmHg and mean seated DBP &lt;80 mmHg at trough
- key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic Systolic and Diastolic Blood Pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No (SBP&gt;=140 and/or DBP&gt;=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3"/>
                    <measurement group_id="O2" value="29.2"/>
                    <measurement group_id="O3" value="41.5"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Normal (140&gt;SBP&gt;=130 and 90&gt;DBP&gt;=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9"/>
                    <measurement group_id="O2" value="29.2"/>
                    <measurement group_id="O3" value="26.4"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (130&gt;SBP&gt;=120 and 85&gt;DBP&gt;=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="30.2"/>
                    <measurement group_id="O3" value="21.7"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Optimal (SBP&lt;120 and DBP&lt;80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="11.5"/>
                    <measurement group_id="O3" value="10.4"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP</title>
        <description>Observed results for mod-sev patients - key combination therapies</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP</title>
          <description>Observed results for mod-sev patients - key combination therapies</description>
          <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" spread="10.8"/>
                    <measurement group_id="O2" value="-16.9" spread="10.8"/>
                    <measurement group_id="O3" value="-13.8" spread="10.1"/>
                    <measurement group_id="O4" value="-13.7" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="12.3"/>
                    <measurement group_id="O2" value="-16.3" spread="12.5"/>
                    <measurement group_id="O3" value="-13.9" spread="9.3"/>
                    <measurement group_id="O4" value="-15.9" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="14.4"/>
                    <measurement group_id="O2" value="-13.8" spread="11.2"/>
                    <measurement group_id="O3" value="-16.4" spread="11.3"/>
                    <measurement group_id="O4" value="-16.1" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="12.4"/>
                    <measurement group_id="O2" value="-16.3" spread="13.6"/>
                    <measurement group_id="O3" value="-15.9" spread="11.8"/>
                    <measurement group_id="O4" value="-16.8" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="10.5"/>
                    <measurement group_id="O2" value="-15.3" spread="14.3"/>
                    <measurement group_id="O3" value="-17.2" spread="14.3"/>
                    <measurement group_id="O4" value="-16.6" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="12.2"/>
                    <measurement group_id="O2" value="-15.3" spread="12.6"/>
                    <measurement group_id="O3" value="-15.2" spread="10.1"/>
                    <measurement group_id="O4" value="-16.3" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" spread="11.1"/>
                    <measurement group_id="O2" value="-15.3" spread="11.4"/>
                    <measurement group_id="O3" value="-12.9" spread="10.9"/>
                    <measurement group_id="O4" value="-17.5" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="13.1"/>
                    <measurement group_id="O2" value="-19.4" spread="13.7"/>
                    <measurement group_id="O3" value="-13.5" spread="14.2"/>
                    <measurement group_id="O4" value="-17.8" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14" spread="11"/>
                    <measurement group_id="O2" value="-16.6" spread="14.2"/>
                    <measurement group_id="O3" value="-15.8" spread="14.3"/>
                    <measurement group_id="O4" value="-18.1" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="11.1"/>
                    <measurement group_id="O2" value="-14.6" spread="14"/>
                    <measurement group_id="O3" value="-17" spread="14.2"/>
                    <measurement group_id="O4" value="-20.8" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="13.9"/>
                    <measurement group_id="O2" value="-14.8" spread="12.6"/>
                    <measurement group_id="O3" value="-16.8" spread="10.5"/>
                    <measurement group_id="O4" value="-17.9" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="12.2"/>
                    <measurement group_id="O2" value="-13.9" spread="12.4"/>
                    <measurement group_id="O3" value="-14.3" spread="12.2"/>
                    <measurement group_id="O4" value="-16.6" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="13"/>
                    <measurement group_id="O2" value="-14.9" spread="14.5"/>
                    <measurement group_id="O3" value="-14.1" spread="12.5"/>
                    <measurement group_id="O4" value="-15.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="14.3"/>
                    <measurement group_id="O2" value="-14.5" spread="14.6"/>
                    <measurement group_id="O3" value="-15.1" spread="11.2"/>
                    <measurement group_id="O4" value="-12" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="16.6"/>
                    <measurement group_id="O2" value="-10.5" spread="13.6"/>
                    <measurement group_id="O3" value="-13.8" spread="14.7"/>
                    <measurement group_id="O4" value="-10" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="15"/>
                    <measurement group_id="O2" value="-10.3" spread="16.3"/>
                    <measurement group_id="O3" value="-12.8" spread="12.2"/>
                    <measurement group_id="O4" value="-13.7" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="14.1"/>
                    <measurement group_id="O2" value="-9.8" spread="14.9"/>
                    <measurement group_id="O3" value="-11.5" spread="12.5"/>
                    <measurement group_id="O4" value="-12.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="15.6"/>
                    <measurement group_id="O2" value="-9.9" spread="13.5"/>
                    <measurement group_id="O3" value="-10.6" spread="10.3"/>
                    <measurement group_id="O4" value="-12.8" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" spread="11.7"/>
                    <measurement group_id="O2" value="-11.6" spread="13.9"/>
                    <measurement group_id="O3" value="-12.2" spread="10.6"/>
                    <measurement group_id="O4" value="-12.5" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" spread="12.3"/>
                    <measurement group_id="O2" value="-10.9" spread="13.1"/>
                    <measurement group_id="O3" value="-13.3" spread="11.2"/>
                    <measurement group_id="O4" value="-15.7" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="12.3"/>
                    <measurement group_id="O2" value="-8.6" spread="14.3"/>
                    <measurement group_id="O3" value="-8.4" spread="12.1"/>
                    <measurement group_id="O4" value="-15.1" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="11.3"/>
                    <measurement group_id="O2" value="-10" spread="14.6"/>
                    <measurement group_id="O3" value="-10.2" spread="13.5"/>
                    <measurement group_id="O4" value="-15.2" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" spread="11.8"/>
                    <measurement group_id="O2" value="-14" spread="13.8"/>
                    <measurement group_id="O3" value="-10" spread="12.5"/>
                    <measurement group_id="O4" value="-14.3" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" spread="9.8"/>
                    <measurement group_id="O2" value="-13.6" spread="11.2"/>
                    <measurement group_id="O3" value="-13.2" spread="13.8"/>
                    <measurement group_id="O4" value="-14.4" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ABPM 24-hour Mean DBP</title>
        <description>Observed results for mod-sev patients - key combination therapies</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ABPM 24-hour Mean DBP</title>
          <description>Observed results for mod-sev patients - key combination therapies</description>
          <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" spread="7.7"/>
                    <measurement group_id="O2" value="-13.6" spread="8"/>
                    <measurement group_id="O3" value="-13.6" spread="7.1"/>
                    <measurement group_id="O4" value="-15.3" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ABPM 24-hour Mean SBP</title>
        <description>Observed results for mod-sev patients - key combination therapies</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tabl plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ABPM 24-hour Mean SBP</title>
          <description>Observed results for mod-sev patients - key combination therapies</description>
          <population>FAS-ABPM: all patients of the FAS that participated in the ambulatory blood pressure monitoring (ABPM) sub-study and had a successful APBM at both baseline and following treatment with target therapy.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="11.3"/>
                    <measurement group_id="O2" value="-20.8" spread="14.1"/>
                    <measurement group_id="O3" value="-20.9" spread="11"/>
                    <measurement group_id="O4" value="-22.7" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Orthostatic Change in Trough Cuff Mean DBP</title>
        <description>Calculated as seated minus standing for mod-sev patients - key combination therapies</description>
        <time_frame>Week 8</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Orthostatic Change in Trough Cuff Mean DBP</title>
          <description>Calculated as seated minus standing for mod-sev patients - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic diastolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="5.1"/>
                    <measurement group_id="O2" value="2" spread="5.7"/>
                    <measurement group_id="O3" value="1.4" spread="5.3"/>
                    <measurement group_id="O4" value="1.6" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Orthostatic Change in Trough Cuff Mean SBP</title>
        <description>Calculated as seated minus standing for mod-sev patients - key combination therapies</description>
        <time_frame>Week 8</time_frame>
        <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic systolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Orthostatic Change in Trough Cuff Mean SBP</title>
          <description>Calculated as seated minus standing for mod-sev patients - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough cuff blood pressure measurements included all treated patients that had at least one in-clinic systolic blood pressure measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="7.1"/>
                    <measurement group_id="O2" value="1.4" spread="8.1"/>
                    <measurement group_id="O3" value="0.1" spread="6.9"/>
                    <measurement group_id="O4" value="1.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Seated Trough Pulse Rate</title>
        <description>Observed results for mod-sev patients - key combination therapies</description>
        <time_frame>Up to 8 weeks (LOCF)</time_frame>
        <population>The full analysis set relating to the in-clinic trough pulse rate measurements included all treated patients that had at least one in-clinic pulse rate measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
            <description>T40mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
            <description>T40mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
            <description>T80mg tab plus encapsulated A5mg capsule, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
            <description>T80mg tab plus 2 encapsulated A5mg capsule, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Trough Pulse Rate</title>
          <description>Observed results for mod-sev patients - key combination therapies</description>
          <population>The full analysis set relating to the in-clinic trough pulse rate measurements included all treated patients that had at least one in-clinic pulse rate measurement following treatment with target therapy and were identified as having moderate or severe hypertension at baseline (FAS-TC-MS).</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="8.8"/>
                    <measurement group_id="O2" value="0" spread="9"/>
                    <measurement group_id="O3" value="2.5" spread="9.2"/>
                    <measurement group_id="O4" value="-1.9" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Laboratory Parameters and Electrocardiogram (ECG)</title>
        <description>Clinical relevant abnormalities for laboratory parameters and Electrocardiogram (ECG). New abnormal findings or worsening of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).</description>
        <time_frame>8 weeks</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Pl)</title>
            <description>placebo tablet plus encapsulated placebo tablet, QD in morning</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan Monotherapy</title>
            <description>Telmisartan 20/40/80mg tablet, QD in morning</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine Monotherapy</title>
            <description>encapsulated Amlodipine 2.5/5 mg capsule or 2 x 5mg capsules, QD in morning</description>
          </group>
          <group group_id="O4">
            <title>Combination Therapy</title>
            <description>Telmisartan 20/40/80mg tablet plus 2.5/5 mg capsule or 2 x 5mg capsules, QD in morning</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Laboratory Parameters and Electrocardiogram (ECG)</title>
          <description>Clinical relevant abnormalities for laboratory parameters and Electrocardiogram (ECG). New abnormal findings or worsening of baseline conditions were reported as Adverse Events related to treatment (cardiac disorders and investigations).</description>
          <population>Treated set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="319"/>
                <count group_id="O4" value="789"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood potassium increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Electrocardiogram QT shortened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.3"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Electrocardiogram T wave abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.3"/>
                    <measurement group_id="O4" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Electrocardiogram repolarisation abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate irregular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.3"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS axis abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.3"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrioventricular block first degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left atrial dilatation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial ischaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.1"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.6"/>
                    <measurement group_id="O4" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinus bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PLACEBO</title>
        </group>
        <group group_id="E2">
          <title>Telmisartan 20 mg (T20)</title>
        </group>
        <group group_id="E3">
          <title>Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5)</title>
        </group>
        <group group_id="E4">
          <title>Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5)</title>
        </group>
        <group group_id="E5">
          <title>Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10)</title>
        </group>
        <group group_id="E6">
          <title>Telmisartan 40 mg (T40)</title>
        </group>
        <group group_id="E7">
          <title>Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5)</title>
        </group>
        <group group_id="E8">
          <title>Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5)</title>
        </group>
        <group group_id="E9">
          <title>Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10)</title>
        </group>
        <group group_id="E10">
          <title>Telmisartan 80 mg (T80)</title>
        </group>
        <group group_id="E11">
          <title>Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5)</title>
        </group>
        <group group_id="E12">
          <title>Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5)</title>
        </group>
        <group group_id="E13">
          <title>Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10)</title>
        </group>
        <group group_id="E14">
          <title>Amlodipine 2.5 mg (A2.5)</title>
        </group>
        <group group_id="E15">
          <title>Amlodipine 5 mg (A5)</title>
        </group>
        <group group_id="E16">
          <title>Amlodipine 10 mg (A10)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6"/>
                <counts group_id="E2" subjects_affected="5"/>
                <counts group_id="E3" subjects_affected="4"/>
                <counts group_id="E4" subjects_affected="5"/>
                <counts group_id="E5" subjects_affected="6"/>
                <counts group_id="E6" subjects_affected="13"/>
                <counts group_id="E7" subjects_affected="3"/>
                <counts group_id="E8" subjects_affected="9"/>
                <counts group_id="E9" subjects_affected="13"/>
                <counts group_id="E10" subjects_affected="5"/>
                <counts group_id="E11" subjects_affected="1"/>
                <counts group_id="E12" subjects_affected="10"/>
                <counts group_id="E13" subjects_affected="23"/>
                <counts group_id="E14" subjects_affected="2"/>
                <counts group_id="E15" subjects_affected="10"/>
                <counts group_id="E16" subjects_affected="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="130"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="143"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="142"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E16" subjects_affected="23" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="130"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="143"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="142"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

